الفهرس 
INTRODUCTIONOnly 14 pages are availabe for public view
 |  | from | 289 |  |  |
| | | from | 289 | | |
Abstract
Narrow Therapeutic Index (NTI) medications represent a major problem for clinicians,
pharmacists and patients. Significant variability in quality and efficacy commonly exist upon
switching across generic NTI products compared to their brands and even within brand
products themselves. (1) Numerous studies have shown differences in the bioequivalence and
clinical performance between several NTI generics and/or NTI multi-source brand products,
such as Carbamazepine (Tegretol®), Phenytoin (Epanutin®), Thyroxine (Eltroxin®) and
Warfarin (Marevan®). However, this problem has been marginalized in pharmaceutical
research field for several decades, which consequently augments the need for comparing and
evaluating the pharmaceutical quality, stability and efficacy of generics and/or brand products
marketed under the same brand name or manufactured in different countries under its own
licensing trademark™. (2) Market surveys have shown that Egypt is one of the countries
suffering from this problem (Table1).